|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||
  British Journal of HaematologyVolume 138 Issue 5, Pages 640 - 643 Published Online: 2 Aug 2007 © 2010 Blackwell Publishing Ltd The Official Journal of the British Society for Haematology
Abstract | References | Full Text: HTML, PDF (Size: 490K) | Related Articles | Citation Tracking  short report Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy Preliminary results were presented in abstract form at the American Society of Hematology 48th Annual Meeting and Exposition, Orlando, FL, USA (December 9–12, 2006). Copyright 2007 The Authors Journal Compilation 2007 Blackwell Publishing Ltd KEYWORDS dexamethasone • combination therapy • lenalidomide • myeloma • renal insufficiency ABSTRACTData on 72 patients receiving lenalidomide/dexamethasone for multiple myeloma (MM) was used to determine the factors that are associated with lenalidomide-induced myelosuppression. Eight of 14 patients with grade ≥3 myelosuppression had baseline creatinine clearance (CrCl) ≤0·67 ml/s. Kaplan–Meier analysis by log-rank test demonstrated a significant association (P < 0·0001) between renal insufficiency and time to myelosuppression (hazard ratio = 8·4; 95% confidence interval 2·9–24·7, P = 0·0001). Therefore, CrCl is inversely associated with significant myelosuppression. Caution should be exercised when lenalidomide therapy is commenced and CrCl should be incorporated as a determinant of the initial dosing of lenalidomide in MM patients. Received 27 April 2007; accepted for publication 11 May 2007 | 
|
